cositecan has been researched along with camptothecin in 19 studies
| Studies (cositecan) | Trials (cositecan) | Recent Studies (post-2010) (cositecan) | Studies (camptothecin) | Trials (camptothecin) | Recent Studies (post-2010) (camptothecin) |
|---|---|---|---|---|---|
| 20 | 5 | 2 | 13,002 | 2,229 | 5,391 |
| Protein | Taxonomy | cositecan (IC50) | camptothecin (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.05 | |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 7.4 | |
| DNA topoisomerase 1 | Homo sapiens (human) | 1.9799 | |
| Somatostatin receptor type 1 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 2 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 4 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 3 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 5 | Homo sapiens (human) | 0.0022 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.97 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.05 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.05 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (89.47) | 29.6817 |
| 2010's | 2 (10.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azrak, RG; Frank, C; Guo, B; Minderman, H; Rustum, YM; Slocum, HK; Vanhoefer, U; Wrzosek, C; Yin, MB | 1 |
| Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH | 2 |
| Boven, E; Hoogsteen, I; Pinedo, HM; Schlüper, HM; Van Hattum, AH | 1 |
| Bigner, DD; Friedman, HS; Hausheer, F; Keir, ST; Lawless, AA | 1 |
| Hausheer, F; Madden, TL; Newman, RA; Smith, JA | 1 |
| Azrak, RG; Frank, C; Hapke, G; Rustum, YM; Wrzosek, C; Wu, J; Yin, MB | 1 |
| Bailly, C; Lansiaux, A | 1 |
| Hausheer, FH; Madden, T; Newman, RA; Smith, JA | 1 |
| Aleksic, A; Berg, SL; Blaney, SM; Dauser, R; Hausheer, F; Kerr, JZ; McGuffey, L; Nuchtern, JG; Thompson, PA | 1 |
| Berghorn, E; Centeno, B; Daud, A; Deconti, RC; Derderian, J; Hausheer, F; Liu, Z; Munster, P; Sullivan, D; Sullivan, P; Urbas, P; Valkov, N | 1 |
| Green, MR; Gu, L; Herndon, JE; Miller, AA | 1 |
| Berg, SL; Blaney, SM; D'Argenio, DZ; Jacob, E; Scorsone, K | 1 |
| Batchelor, T; Carson, KA; Grossman, SA; Hausheer, F; Lesser, G; Nabors, LB; Peereboom, D; Phuphanich, S; Supko, JG | 1 |
| Beijnen, JH; Kenworthy, KE; Oostendorp, RL; Schellens, JH; Schinkel, AH; van de Steeg, E; van der Kruijssen, CM | 1 |
| Bastien, S; Bicaku, E; Daud, AI; Dawson, J; DeConti, RC; Hausheer, FA; Lush, R; Marchion, D; Munster, PN; Neuger, A; Sullivan, DM | 1 |
| Pappo, A; Paulino, AC | 1 |
| Daud, AI; Munster, PN | 1 |
| Chen, X; Ding, D; Hausheer, F; Huang, Q; Kochat, H; Parker, A; Petluru, P; Yao, S | 1 |
1 review(s) available for cositecan and camptothecin
| Article | Year |
|---|---|
Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.
Topics: Animals; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Humans; Melanoma; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors | 2011 |
4 trial(s) available for cositecan and camptothecin
| Article | Year |
|---|---|
Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
Topics: Adult; Aged; Anemia; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Fatigue; Female; HL-60 Cells; Humans; Male; Melanoma; Middle Aged; Nausea; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2005 |
Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).
Topics: Aged; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 2005 |
Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Drug Interactions; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local | 2008 |
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Histones; Humans; Male; Melanoma; Mice; Mice, Nude; Middle Aged; Skin Neoplasms; Topoisomerase I Inhibitors; Valproic Acid | 2009 |
14 other study(ies) available for cositecan and camptothecin
| Article | Year |
|---|---|
Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.
Topics: Camptothecin; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cell Division; Checkpoint Kinase 1; Cyclin B; DNA Fragmentation; DNA Topoisomerases, Type I; Electrophoresis, Gel, Pulsed-Field; Head and Neck Neoplasms; Humans; Phosphorylation; Protein Kinases; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2000 |
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
New analogues of camptothecins. Activity and resistance.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Female; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous | 2001 |
Development of a high-performance liquid chromatographic method to determine the concentration of karenitecin, a novel highly lipophilic camptothecin derivative, in human plasma and urine.
Topics: Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2001 |
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Division; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350.
Topics: 14-3-3 Proteins; Camptothecin; Cell Division; Checkpoint Kinase 1; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Enzyme Inhibitors; G2 Phase; Humans; Mitosis; Oligonucleotides, Antisense; Phosphorylation; Protein Kinases; Signal Transduction; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tyrosine 3-Monooxygenase | 2002 |
[A symphony for the camptothecins].
Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan | 2003 |
Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; In Vitro Techniques; Isoenzymes; Orosomucoid; Protein Binding; Serum Albumin | 2003 |
Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Catheters, Indwelling; Injections, Intravenous; Macaca mulatta; Topoisomerase I Inhibitors | 2004 |
Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Child; Cyclophosphamide; Drug Synergism; Humans; Leukemia; Medulloblastoma; Neuroblastoma | 2008 |
Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line; Dogs; Humans; Liver-Specific Organic Anion Transporter 1; Neoplasm Proteins; Organic Anion Transporters | 2009 |
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine | 2009 |
Stabilization of the Karenitecin® lactone by alpha-1 acid glycoprotein.
Topics: Antineoplastic Agents; Binding Sites; Camptothecin; Chromatography, High Pressure Liquid; Drug Stability; Humans; Hydrolysis; Kinetics; Lactones; Molecular Structure; Orosomucoid; Protein Binding; Serum Albumin | 2015 |